SMMT (STOCKS)
Summit Therapeutics Inc. Common Stock
$19.971700
+0.301700 (+1.53%)
Prev close: $19.670000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Robert William Duggan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $15,519.08M
- Employees
- 159
- P/E (TTM)
- -13.86
- P/B (TTM)
- 23.15
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
13
Buy
5
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.29 | $-0.07 | -0.2244 | -342.07% |
|
Sep 2025 (Q3)
|
$-0.31 | $-0.13 | -0.1755 | -130.48% |
|
Jun 2025 (Q2)
|
$-0.12 | $-0.10 | -0.0236 | -24.48% |
|
Mar 2025 (Q1)
|
$-0.09 | $-0.09 | +0.0028 | +3.02% |
Financial Statements
| Nonoperating Income/Loss | $14.84M |
| Operating Expenses | $1.09B |
| Income/Loss From Continuing Operations After Tax | -$1.08B |
| Income/Loss From Continuing Operations Before Tax | -$1.08B |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$1.08B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$1.08B |
| Net Income/Loss Available To Common Stockholders, Basic | -$1.08B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.44 |
| Diluted Earnings Per Share | -$1.44 |
| Basic Average Shares | 747,702,265 |
| Diluted Average Shares | 747,702,265 |
| Assets | $751.18M |
| Current Assets | $720.30M |
| Noncurrent Assets | $30.88M |
| Fixed Assets | $1.06M |
| Other Non-current Assets | $29.82M |
| Liabilities | $92.32M |
| Current Liabilities | $72.99M |
| Accounts Payable | $20.29M |
| Wages | $14.93M |
| Other Current Liabilities | $37.77M |
| Noncurrent Liabilities | $19.33M |
| Equity | $658.86M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $658.86M |
| Liabilities And Equity | $751.18M |
| Net Cash Flow From Operating Activities | -$322.93M |
| Net Cash Flow From Operating Activities, Continuing | -$322.93M |
| Net Cash Flow From Investing Activities | -$174.31M |
| Net Cash Flow From Investing Activities, Continuing | -$174.31M |
| Net Cash Flow From Financing Activities | $617.53M |
| Net Cash Flow From Financing Activities, Continuing | $617.53M |
| Net Cash Flow | $120.29M |
| Net Cash Flow, Continuing | $120.29M |
| Comprehensive Income/Loss | -$1.08B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$1.08B |
| Other Comprehensive Income/Loss | -$1.08B |
| Other Comprehensive Income/Loss Attributable To Parent | -$255.00K |